GSK plc

NYSE:GSK Stock Report

Market Cap: US$107.2b

GSK Future Growth

Future criteria checks 2/6

GSK is forecast to grow earnings and revenue by 4.2% and 3.6% per annum respectively. EPS is expected to grow by 5.2% per annum. Return on equity is forecast to be 30.1% in 3 years.

Key information

4.2%

Earnings growth rate

5.19%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate3.6%
Future return on equity30.15%
Analyst coverage

Good

Last updated03 Jul 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jun 25

Is GSK Quietly Becoming An Oncology Powerhouse

Summary GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver. So, sales of Exdensur, a twice-yearly add-on maintenance treatment of severe asthma, were $15 million in its first full quarter following FDA approval. I will nextdiscuss other factors that, in my view, make GSK’s risk/reward profileattractive. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'

Summary GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the fourth quarter of 2024, more than tripling year-on-year. While sales of the HIV therapy called Cabenuva also did not disappoint, totaling $396 million, up 23.8% quarter-on-quarter. GSK also raised its 2031 sales outlook to £40 billion from £38 billion. In this article, you will learn about other reasons why I am upgrading GSK's rating from 'Buy' to 'Strong Buy.' Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:GSK - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202836,7276,8096,44410,14516
12/31/202735,5596,9356,0859,83418
12/31/202633,8616,4715,6809,60617
3/31/202632,7805,8294,8587,737N/A
12/31/202532,6675,7164,8717,741N/A
9/30/202532,1665,4944,8147,792N/A
6/30/202531,6313,4234,8457,724N/A
3/31/202531,5293,1534,0546,741N/A
12/31/202431,3762,5753,7036,554N/A
9/30/202431,3112,5114,9177,421N/A
6/30/202431,4464,0335,2227,479N/A
3/31/202430,7404,4845,3307,673N/A
12/31/202330,3284,9284,4366,768N/A
9/30/202329,6526,0783,2475,477N/A
6/30/202329,3345,3732,4864,586N/A
3/31/202329,0854,4552,8924,914N/A
12/31/202229,3244,4615,3417,403N/A
9/30/202229,0243,3877,6209,265N/A
6/30/202227,8223,5058,07310,506N/A
3/31/202226,7314,0137,61110,163N/A
12/31/202124,6963,3165,9397,952N/A
9/30/202126,3593,5676,0648,040N/A
6/30/202128,3783,9344,8716,339N/A
3/31/202130,1644,9837,0287,807N/A
12/31/202024,3544,8736,8398,441N/A
9/30/202034,2596,3716,8338,039N/A
6/30/202034,9986,6798,7519,693N/A
3/31/202035,1835,3806,6288,322N/A
12/31/201933,7544,645N/A8,020N/A
9/30/201933,0524,561N/A8,686N/A
6/30/201931,7594,427N/A8,248N/A
3/31/201931,2603,904N/A8,221N/A
12/31/201830,8213,623N/A8,421N/A
9/30/201830,2631,862N/A7,171N/A
6/30/201830,0141,656N/A6,991N/A
3/31/201830,0241,035N/A6,637N/A
12/31/201730,1861,532N/A6,918N/A
9/30/201730,1332,335N/A7,040N/A
6/30/201729,8321,931N/A6,910N/A
3/31/201729,0441,676N/A7,138N/A
12/31/201627,889912N/A6,497N/A
9/30/201626,589301N/A5,007N/A
6/30/201625,17431N/A3,721N/A
3/31/201624,530615N/A2,702N/A
12/31/201523,9238,422N/A2,569N/A
9/30/201523,8239,809N/A3,278N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GSK's forecast earnings growth (4.2% per year) is above the savings rate (3.5%).

Earnings vs Market: GSK's earnings (4.2% per year) are forecast to grow slower than the US market (18.4% per year).

High Growth Earnings: GSK's earnings are forecast to grow, but not significantly.

Revenue vs Market: GSK's revenue (3.6% per year) is forecast to grow slower than the US market (12.7% per year).

High Growth Revenue: GSK's revenue (3.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GSK's Return on Equity is forecast to be high in 3 years time (30.1%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 06:10
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 47 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
Xue ChenBarclays